EASL 2016 Signing of the Joint Society Statement on Elimination of Viral Hepatitis. Photo by Liz Highleyman, hivandhepatitis.comJoint statementLiver associations worldwide call for elimination of viral hepatitis. WebinarSlides and audio from our conference webinar. Dr James Freeman presenting at ILC 2016. Photo by Liz Highleyman, hivandhepatitis.comGeneric drugsLow-cost generic hepatitis C drugs match branded products in viral responses. infohep news Antiviral therapy Hepatitis B treatment may be linked to colorectal and cervical cancer Liz Highleyman / 10 June 2016 People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have a higher rate of malignancies overall, but did show an increased incidence of colorectal and cervical cancer, underlining the ... Antiviral therapy Antiviral therapy linked to lower liver cancer and mortality in people with mild hepatitis B Liz Highleyman / 17 May 2016 Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver ... Treatment for people living with HIV and HCV Does having HIV affect response to hepatitis C treatment? Liz Highleyman / 16 May 2016 A study from the US Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that ... Cirrhosis Emricasan may improve inflammation and liver function in people with cirrhosis Liz Highleyman / 13 May 2016 The novel caspase inhibitor emricasan led to improvements in various biomarkers and decreases in MELD scores in patients with liver cirrhosis due to hepatitis C, heavy alcohol use or other causes, with significant ... Treatment guidelines WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September Liz Highleyman / 12 May 2016 In April, coinciding with the 2016 International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the screening, care and treatment of patients with chronic hepatitis ... NorUrsodeoxycholic acid helps rare bile duct disease with no current treatment Liz Highleyman / 09 May 2016 A phase 2 European trial showed that norUrsodeoxycholic acid leads to a significant reduction in serum alkaline phosphatase in people with primary sclerosing cholangitis, a rare but serious bile duct disease, according to ... Treatment for people who use drugs Hepatitis C therapy improves quality of life for people who inject drugs, but reinfection risk remains Liz Highleyman / 06 May 2016 People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at ... New and experimental treatments for hepatitis B Core inhibitor NVR 3-778 plus pegylated interferon inhibits hepatitis B activity Liz Highleyman / 05 May 2016 NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA and hepatitis B 'e' antigen (HBeAg), showing greater activity when ... Finance, funding & health economics Cost of eliminating viral hepatitis needs to take into account social as well as medical burden of disease Keith Alcorn / 04 May 2016 Securing commitments from national governments to treat viral hepatitis, scale up prevention activities and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces – ... Hepatocellular carcinoma (HCC) People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence Liz Highleyman / 28 April 2016 Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history ... View more > Editors' picks from other sources Mother to child Antiviral prophylaxis cost-effective to prevent perinatal HBV transmission Healio / 11 May 2016 Hepatitis delta Study demonstrates benefits of existing treatment for hepatitis D patients EASL press release / 15 April 2016 Antiviral therapy Antiviral therapy prolongs survival in immune tolerant hepatitis B patients Eurekalert Inf Dis / 15 April 2016 Antiviral therapy Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer EASL press release / 15 April 2016 Liver transplants New HCV Therapies Might Ease Transplant Pressure MedPage Today Gastroenterology / 15 April 2016 Hepatocellular carcinoma (HCC) Nearly one-third of patients with previous HCC recur after DAA therapy Healio Hepatology / 15 April 2016 Treatment outcomes One year after universal HCV treatment, Portugal shows 96% SVR rate Healio Hepatology / 14 April 2016 Liver transplants Hepatitis C infected livers offer similar outcomes to healthy livers in those waiting for liver transplants EASL press release / 14 April 2016 Testing for hepatitis C Research shows doctors are failing to diagnose more than 50% of patients with hepatitis C virus (HCV) World Hepatitis Alliance / 14 April 2016 Transmission, epidemiology and prevention Combined HIV and hepatitis C virus vaccination a possibility EASL press release / 13 April 2016 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive